Shenyang Pharma Univ. CYP1B1 compound C27

Shenyang Pharma Univ. CYP1B1 compound C27: sourced facts only. name: "Among these, the preferred compound C27 exhibited an IC50 value of 1.47 nM against CYP1B1 and demonstrated high selectivity over six major CYP isoforms." [PMID:42401084]; target: "Among these, the preferred compound C27 exhibited an IC50 value of 1.47 nM against CYP1B1 and demonstrated high selectivity over six major CYP isoforms." [PMID:42401084]; developer: "Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China; Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China." [PMID:42401084]; stage: "In the A549/Taxol drug-resistant cell model, C27 significantly enhanced the inhibitory effect of paclitaxel on the proliferation of resistant cells and effectively inhibited tumor cell migration and invasion." [PMID:42401084]